Title
Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study
Date Issued
01 September 2022
Access level
open access
Resource Type
journal article
Author(s)
Finci I.
Albertini A.
Merker M.
Andres S.
Bablishvili N.
Barilar I.
Crudu V.
Hapeela N.
Hoffmann H.
Hoogland C.
Kohl T.A.
Kranzer K.
Mantsoki A.
Maurer F.P.
Nicol M.P.
Noroc E.
Plesnik S.
Rodwell T.
Ruhwald M.
Savidge T.
Salfinger M.
Streicher E.
Tukvadze N.
Warren R.
Zemanay W.
Zurek A.
Niemann S.
Denkinger C.M.
Publisher(s)
Elsevier Ltd
Abstract
Background: Whole-genome sequencing (WGS) of Mycobacterium tuberculosis complex has become an important tool in diagnosis and management of drug-resistant tuberculosis. However, data correlating resistance genotype with quantitative phenotypic antimicrobial susceptibility testing (AST) are scarce. Methods: In a prospective multicentre observational study, 900 clinical M tuberculosis complex isolates were collected from adults with drug-resistant tuberculosis in five high-endemic tuberculosis settings around the world (Georgia, Moldova, Peru, South Africa, and Viet Nam) between Dec 5, 2014, and Dec 12, 2017. Minimum inhibitory concentrations (MICs) and resulting binary phenotypic AST results for up to nine antituberculosis drugs were determined and correlated with resistance-conferring mutations identified by WGS. Findings: Considering WHO-endorsed critical concentrations as reference, WGS had high accuracy for prediction of resistance to isoniazid (sensitivity 98·8% [95% CI 98·5–99·0]; specificity 96·6% [95% CI 95·2–97·9]), levofloxacin (sensitivity 94·8% [93·3–97·6]; specificity 97·1% [96·7–97·6]), kanamycin (sensitivity 96·1% [95·4–96·8]; specificity 95·0% [94·4–95·7]), amikacin (sensitivity 97·2% [96·4–98·1]; specificity 98·6% [98·3–98·9]), and capreomycin (sensitivity 93·1% [90·0–96·3]; specificity 98·3% [98·0–98·7]). For rifampicin, pyrazinamide, and ethambutol, the specificity of resistance prediction was suboptimal (64·0% [61·0–67·1], 83·8% [81·0–86·5], and 40·1% [37·4–42·9], respectively). Specificity for rifampicin increased to 83·9% when borderline mutations with MICs overlapping with the critical concentration were excluded. Consequently, we highlighted mutations in M tuberculosis complex isolates that are often falsely identified as susceptible by phenotypic AST, and we identified potential novel resistance-conferring mutations. Interpretation: The combined analysis of mutations and quantitative phenotypes shows the potential of WGS to produce a refined interpretation of resistance, which is needed for individualised therapy, and eventually could allow differential drug dosing. However, variability of MIC data for some M tuberculosis complex isolates carrying identical mutations also reveals limitations of our understanding of the genotype and phenotype relationships (eg, including epistasis and strain genetic background). Funding: Bill & Melinda Gates Foundation, German Centre for Infection Research, German Research Foundation, Excellence Cluster Precision Medicine of Inflammation (EXC 2167), and Leibniz ScienceCampus EvoLUNG.
Start page
e672
End page
e682
Volume
3
Issue
9
Language
English
OCDE Knowledge area
Sistema respiratorio
Scopus EID
2-s2.0-85135895993
Source
The Lancet Microbe
ISSN of the container
26665247
Sponsor(s)
We thank the Bill & Melinda Gates Foundation, the German Research Foundation under the Germany's Excellence Strategy for the Excellence Cluster Precision Medicine in Chronic Inflammation EXC 2167, the German Center for Infection Research, and Evolutionary Medicine of the Lung at Leibniz ScienceCampus for funding these activities. We thank all participants for taking part in the study and providing clinical samples, and the clinical teams involved in the study for their work. Our special thanks to the teams at Kwazulu-Natal Research Institute for Tuberculosis and HIV, and at the Pham Ngoc Thac Tuberculosis and Lung Disease Hospital for the coordination of some of the collections in South Africa and Viet Nam. We would also like to acknowledge the teams at the Molecular and Experimental Mycobacteriology and Diagnostic Mycobacteriology in Borstel, Germany, for excellent technical assistance. RW and ES acknowledge baseline support from the SAMRC.
Sources of information:
Directorio de Producción Científica
Scopus